WALTHAM, Mass.--(BUSINESS WIRE)--May 12, 2021-- PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.
The Cellaca MX High-throughput Cell Counter from Nexcelom Bioscience has been nominated for a Scientists’ Choice Award
We are delighted to announce that, thanks to our loyal customers, the Cellaca™ MX High-throughput Cell Counter has been nominated in the Life Sciences category.
Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated cell counter – Cellaca™ MX.
The latest news from Nexcelom Bioscience March 20, 2018 - Nexcelom Bioscience announces strategic growth investment from Ampersand Capital Partners (PDF) March 20, 2018, Lawrence, MA -- Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom’s worldwide growth initiatives. Founded in 2003, Nexcelom is a fast-growing supplier of innovative cellular analysis instruments, software and related consumables used in a broad range of research fields including immuno-oncology, cell therapy, drug discovery, [...]